Dollars for Profs

Dig Into University Researchers' Outside Income and Conflicts of Interest

Published Dec. 6, 2019

This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.

Financial doc
Filing Type

Conflict of Interest

Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.

Should you be removed from our database? Contact us at [email protected]. Read more below.

Shridar Ganesan

Case Western Reserve University, Department: Biomedical Engineering

Should you be removed from our database? Contact us at [email protected]. Read more below.

Disclosed Conflict of Interest with

Inspirata, Inc.

Disclosed Value
Listed Reason
Intellectual property rights (e.g., royalties, patents, copyrights) not from the awardee Institution

Please note, that Ibris, Inc, the 2nd company referenced in the Dr. Ganesan's attached report from Rutgers, was acquired by Inspirata in 2015 and the intellectual property was re-assigned to Inspirata during acquisition.

Listed Research Project
Computerized histologic image predictor of cancer outcome

RELEVANCE: Of the 1 million women worldwide who in 2015 will be diagnosed with estrogen receptor positive (ER+) breast cancer, most will be treated with chemotherapy, though only a small number (< 20%) will benefit from it. Our goal is to create and validate a pre-commercial prototype of a computerized histologic image based predictor (CHIP) for identifying which early stage ER+ breast cancer patients will benefit from adjuvant chemotherapy. CHIP will employ sophisticated computer vision techniques for comprehensive characterization of disease morphology from digitized images of H&E stained specimens yielding a continuous image-based risk score; low CHIP risk score suggesting hormonal therapy is sufficient while adjuvant chemo is required for high CHIP score patients.

Filed on August 01, 2017.

Tell us what you know about Shridar Ganesan's disclosure

We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?

Name Institution Type Company Disclosed Value
Shridar Ganesan Case Western Reserve University Conflict of Interest Inspirata, Inc. $60,000 - $79,999
If you see an error in the database or a reason we should not disclose a record, please contact us at [email protected] and we'll evaluate it on a case-by-case basis.
Sources: National Institutes of Health, public records requests filed at multiple public state universities

Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.

Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.

ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.

Close Comment Creative Commons Donate Email Facebook Mobile Phone Podcast Print RSS Search Search Twitter WhatsApp
Current site Current page